Try our beta test site

A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD) (PREFER)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: February 6, 2014
Last updated: December 2, 2016
Last verified: September 2016
The purpose of this study is to establish the prevalence of comorbidities in Italian patients with chronic bronchitis with at least 2 exacerbations per year, and to document the appropriateness of instrumental diagnostic tests, such as spirometry of these patients.

Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Prevalence of Comorbidities of COPD in the Exacerbator Phenotype - A Cross Sectional Disease/Condition Focused Observational Study on COPD

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of Comorbidities [ Time Frame: Comorbidities captured at the index visit and related to 12 Months Prior to Study Index Visit ]
    The following comorbidities were accounted for (from the patient records): arterial hypertension, ischemic heart disease, other cardiac disorders, arrhythmia, congestive heart failure, diabetes, metabolic syndrome, known osteoporosis, depression, and chronic renal insufficiency.

  • Percentage of Participants having Annual Spirometric Tests [ Time Frame: 12 months prior and up to the Study Index Visit ]

Enrollment: 860
Study Start Date: November 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Chronic obstructive pulmonary disease
Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.

Detailed Description:

This is an observational study so participants will only take medication that is presently prescribed by their regular healthcare provider. No additional study medication will be administered. This study will enroll patients who have been previously diagnosed with COPD. This study will look at the medical history and other diseases that have been diagnosed in people who also have COPD.

The study will enroll approximately 3000 patients.

This multi-centre trial will be conducted in Italy. The overall time to participate in this study is at a single, regularly scheduled visit at the pulmonologists office. There will not be any follow up assessments.


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with COPD will be enrolled at hospital and pulmonology departments in Italy.

Inclusion Criteria:

  1. Age 45-85, of either gender.
  2. Signed informed consent.
  3. Known COPD documented by spirometric exams showing fixed non reversible respiratory obstruction.
  4. Forced Expired Volume measured after 1 second expiration (FEV-1) < 50% in a previous test (no time limits).
  5. Symptoms of chronic bronchitis : chronic productive cough for 3 months at least in each of the 2 years prior to the index visits.
  6. On treatment of bronchodilators (no restrictions) for the last 12 months at least.
  7. History of at least 2 exacerbations (moderate/severe) in the last 12 months prior to index visit.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02100332

Veruno (Novara), Italy
Sponsors and Collaborators
Study Director: AstraZeneca AstraZeneca AstraZeneca
  More Information

Responsible Party: AstraZeneca Identifier: NCT02100332     History of Changes
Other Study ID Numbers: RO-2455-402-IT
U1111-1152-9289 ( Registry Identifier: WHO (UTN) )
Study First Received: February 6, 2014
Last Updated: December 2, 2016

Keywords provided by AstraZeneca:
Drug Therapy

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on March 28, 2017